Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$50.90 USD
+0.80 (1.60%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $50.83 -0.07 (-0.14%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VKTX 50.90 +0.80(1.60%)
Will VKTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VKTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VKTX
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know
Should Viking (VKTX) Stock be in Your Portfolio Pre-Q2 Earnings?
VKTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why the Market Dipped But Viking Therapeutics, Inc. (VKTX) Gained Today
Novo Nordisk, Lilly Slide on Roche's Obesity Drug Study Data
Novo Nordisk (NVO) Soars 38% YTD: How Should You Play the Stock?
Other News for VKTX
Viking Therapeutics: Great Clinical Results Do Not Guarantee Commercialization Success
Commit To Buy Viking Therapeutics At $30, Earn 22.7% Using Options
3 Undervalued Biotech Stocks With Breakout Potential
Smart Money Is Betting Big In VKTX Options
3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition